Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 2, 2014, Pages 421-430

  Wang, Tao ^a   Hartner, William C ^a   Gillespie, James W ^b   Praveen, Kulkarni P ^a   Yang, Shenghong ^c   Mei, Leslie A ^a   Petrenko, Valery A ^b   Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b AUBURN UNIVERSITY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Breast cancer targeting; Cancer nanomedicines; Drug delivery; Liposomes; Phage display

Indexed keywords

BREAST CANCER TARGETING; CANCER NANOMEDICINES; DRUG DELIVERY; LIPOSOMES; PHAGE DISPLAY;

ALANINE TRANSAMINASE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASPARTATE AMINOTRANSFERASES; BACTERIOPHAGES; BREAST NEOPLASMS; DOXORUBICIN; DRUG CARRIERS; FEMALE; HUMANS; KI-67 ANTIGEN; LIPOSOMES; MCF-7 CELLS; MICE; MICE, NUDE; NANOMEDICINE; NECROSIS; NEOPLASMS; POLYETHYLENE GLYCOLS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 84895072646     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.08.009     Document Type: Article

References (41)

1. Hutchinson L. Breast cancer: challenges, controversies, breakthroughs. Nat Rev Clin Oncol 2010, 7:669-670.
2. Singaland P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998, 339:900-905.
3. Lammers T., Hennink W.E., Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer 2008, 99:392-397.
4. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999, 51:691-743.
5. Hofheinz R.D., Gnad-Vogt S.U., Beyer U., Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 2005, 16:691-707.
6. Harris L., Batist G., Belt R., Rovira D., Navari R., Azarnia N., et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002, 94:25-36.
7. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006, 66:6732-6740.
8. Gabizon A., Shmeeda H., Horowitz A.T., Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 2004, 56:1177-1192.
9. Petrenko V. Evolution of phage display: from bioactive peptides to bioselective nanomaterials. Expert Opin Drug Deliv 2008, 5:825-836.
10. Kim J., Choi S.P., La S., Seo J.S., Kim K.K., Nam S.H., et al. Constitutive expression of 4-1BB on T cells enhances CD4+ T cell responses. Exp Mol Med 2003, 35:509-517.
11. Cortese R., Monaci P., Luzzago A., Santini C., Bartoli F., Cortese I., et al. Selection of biologically active peptides by phage display of random peptide libraries. Curr Opin Biotechnol 1996, 7:616-621.
12. Krumpeand L.R., Mori T. The use of phage-displayed peptide libraries to develop tumor-targeting drugs. Int J Pept Res Ther. 2006, 12:79-91.
13. Wang T., D'Souza G.G., Bedi D., Fagbohun O.A., Potturi L.P., Papahadjopoulos-Sternberg B., et al. Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein. Nanomedicine (Lond) 2010, 5:563-574.
14. Jayanna P.K., Bedi D., Gillespie J.W., DeInnocentes P., Wang T., Torchilin V.P., et al. Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiency. Nanomedicine 2010, 6:538-546.
15. Wang T., Petrenko V.A., Torchilin V.P. Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity. Mol Pharm 2010, 7:1007-1014.
16. Wang T., Kulkarni N., Bedi D., D'Souza G.G., Papahadjopoulos-Sternberg B., Petrenko V.A., et al. In vitro optimization of liposomal nanocarriers prepared from breast tumor cell specific phage fusion protein. J Drug Target 2011, 19:597-605.
17. Wang T., Kulkarni N., D'Souza G.G., Petrenko V.A., Torchilin V.P. On the mechanism of targeting of phage fusion protein-modified nanocarriers: only the binding peptide sequence matters. Mol Pharm 2011, 8:1720-1728.
18. Wang T., Yang S., Petrenko V.A., Torchilin V.P. Cytoplasmic delivery of liposomes into MCF-7 breast cancer cells mediated by cell-specific phage fusion coat protein. Mol Pharm 2010, 7:1149-1158.
19. Phage display for generating peptide reagents 2008, John Wiley & Sons, Inc, New Jersey. S.T. Brigati JR, P.K. Jayanna, V.A. Petrenko (Eds.).
20. Deleageand G., Roux B. An algorithm for protein secondary structure prediction based on class prediction. Protein Eng 1987, 1:289-294.
21. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003, 24:389-427.
22. Aina O.H., Liu R., Sutcliffe J.L., Marik J., Pan C.X., Lam K.S. From combinatorial chemistry to cancer-targeting peptides. Mol Pharm 2007, 4:631-651.
23. Mori T. Cancer-specific ligands identified from screening of peptide-display libraries. Curr Pharm Des 2004, 10:2335-2343.
24. Wang T., Petrenko V.A., Torchilin V.P. Optimization of landscape phage fusion protein-modified polymeric Peg-Pe micelles for improved breast cancer cell targeting. J Nanomedic Nanotechnol 2012, S4(008).
25. Soekarjo M., Eisenhawer M., Kuhn A., Vogel H. Thermodynamics of the membrane insertion process of the M13 procoat protein, a lipid bilayer traversing protein containing a leader sequence. Biochemistry 1996, 35:1232-1241.
26. Kuhn A. Major coat proteins of bacteriophage Pf3 and M13 as model systems for Sec-independent protein transport. FEMS Microbiol Rev 1995, 17:185-190.
27. Kieferand D., Kuhn A. Hydrophobic forces drive spontaneous membrane insertion of the bacteriophage Pf3 coat protein without topological control. EMBO J 1999, 18:6299-6306.
28. Stopar D., Spruijt R.B., Hemminga M.A. Anchoring mechanisms of membrane-associated M13 major coat protein. Chem Phys Lipids 2006, 141:83-93.
29. Spruijt R.B., Wolfs C.J., Hemminga M.A. Aggregation-related conformational change of the membrane-associated coat protein of bacteriophage M13. Biochemistry 1989, 28:9158-9165.
30. Petrenko V.A., Smith G.P., Gong X., Quinn T. A library of organic landscapes on filamentous phage. Protein Eng 1996, 9:797-801.
31. Kuzmicheva G.A., Jayanna P.K., Sorokulova I.B., Petrenko V.A. Diversity and censoring of landscape phage libraries. Protein Eng Des Sel 2009, 22:9-18.
32. T. Wang. Landscape phage fusion protein-modified pharmaceutical nanocarriers for targeted and cytoplasmic delivery of chemotherapeutics to breast cancer cells in vitro and in vivo. Pharmaceutical Science Dissertations (2012).
33. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
34. Noble C.O., Kirpotin D.B., Hayes M.E., Mamot C., Hong K., Park J.W., et al. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets 2004, 8:335-353.
35. Huober J., Fett W., Nusch A., Neise M., Schmidt M., Wischnik A., et al. A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer. BMC Cancer 2010, 10:2.
36. O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15:440-449.
37. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003, 42:419-436.
38. Fagbohun O.A., Bedi D., Grabchenko N.I., Deinnocentes P.A., Bird R.C., Petrenko V.A. Landscape phages and their fusion proteins targeted to breast cancer cells. Protein Eng Des Sel 2012, 25:271-283.
39. Park J.W. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002, 4:95-99.
40. Colozza M., Azambuja E., Cardoso F., Sotiriou C., Larsimont D., Piccart M.J. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?. Ann Oncol 2005, 16:1723-1739.
41. Lynch E.D., Gu R., Pierce C., Kil J. Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity. Anticancer Drugs 2005, 16:569-579.